Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 37 Carcinoma, Non-Small-Cell Lung 24 Squamous Cell Carcinoma of Head and Neck 18 Melanoma 17 Colorectal Neoplasms 16 Urinary Bladder Neoplasms 11 Breast Neoplasms 11 Liver Neoplasms 10 Biliary Tract Neoplasms 10 Small Cell Lung Carcinoma 9 Prostatic Neoplasms 9 Lung Neoplasms 9 Diabetes Mellitus, Insulin-Dependent, 12 9 Carcinoma, Renal Cell 9 Neoplasms 8 Cholangiocarcinoma 7 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Adenocarcinoma Of Esophagus 6 Stomach Neoplasms 5 Neoplasm Metastasis 5 Mesothelioma, Malignant 5 Fallopian Tube Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 3 Recurrence 3 Mesothelioma 3 Esophageal Squamous Cell Carcinoma 3 Endometrial Neoplasms 3

Interventions

Paclitaxel 3 Carboplatin 3 tremelimumab 1 pembrolizumab 1 necitumumab 1 envafolimab 1 durvalumab 1 anlotinib 1 Nivolumab 1 Gemcitabine 1 Endostatins 1 Drug Therapy 1 Cisplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Squamous Non-small Cell Lung Cancer × tremelimumab × Clear all

NCT03319316 2022-01-10

SOLUTION

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡